

Zolbetuximab







Tumour type: Gastrointestinal Cancers

Therapeutic Indication: Zolbetuximab, a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, with fluoropyrimidine- and platinum-containing chemotherapy, for the firstline treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2 positive. Experimental Arm: Zolbetuximab + Oxaliplatin + Leucovorin + Fluorouracil



© 2024 | European Society for Medical Oncology | ESMO - MCBS 1.1 | All rights reserved worldwide.